RWM
ACAD icon

Rialto Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Rialto Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$179 Sell
8
-4
-33% -$96 ﹤0.01% 1616
2025
Q4 		$321 Buy
12
+5
+71% +$119 ﹤0.01% 1412
2025
Q3 		$150 Buy
7
+5
+250% +$118 ﹤0.01% 1545
2025
Q2 		$44 Buy
+2
New +$37 ﹤0.01% 1647

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Rialto Wealth Management's ACAD Position: Q1 2026 in Review

Rialto Wealth Management reduced its Acadia Pharmaceuticals (ACAD) stake by 33% in Q1 2026, selling an estimated $96 and leaving 8 shares worth $179. The position accounts for ﹤0.01% of the portfolio, ranked #1616.

Rialto Wealth Management first reported a position in ACAD in Q2 2025 and has held it in 4 quarters since. The position peaked at $321 in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Rialto Wealth Management held 8 shares of Acadia Pharmaceuticals worth $179 as of Q1 2026.
  • Rialto Wealth Management sold 4 Acadia Pharmaceuticals shares in Q1 2026, an estimated $96.
  • Acadia Pharmaceuticals made up ﹤0.01% of Rialto Wealth Management's portfolio in Q1 2026, its #1616 holding.
  • Rialto Wealth Management first reported a position in Acadia Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Rialto Wealth Management's Acadia Pharmaceuticals position peaked at $321 in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Rialto Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.